46 results on '"Saraf A"'
Search Results
2. PRO5 Sickle Cell Disease-Related Complication Rates in a Large US Administrative Claims Database: A Retrospective Analysis
3. PRO5 Sickle Cell Disease-Related Complication Rates in a Large US Administrative Claims Database: A Retrospective Analysis
4. PDB67 DIABETES MELLITUS : A SYNONYM TO FUNCTIONAL HYPOPARATHYROIDISM
5. PDB67 DIABETES MELLITUS : A SYNONYM TO FUNCTIONAL HYPOPARATHYROIDISM
6. Pharmacoeconomic Evaluation of Patients Undergoing Hemodialysis At a Tertiary Care Centre
7. TREATMENT OUTCOMES IN LUPUS NEPHRITIS CLASS 3 AND 4
8. Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets
9. Pharmacoeconomic Evaluation of Patients Undergoing Hemodialysis At a Tertiary Care Centre
10. Adoption of Oncology Biosimilars in Europe
11. TREATMENT OUTCOMES IN LUPUS NEPHRITIS CLASS 3 AND 4
12. Clinical Outcomes and Histopathology in Idiopathic Membranous Nephropathy Correlation with Serum Antibodies to Phospholipase A 2 Receptor (Anti Pla2r)
13. Adoption of Oncology Biosimilars in Europe
14. Clinical Outcomes and Histopathology in Idiopathic Membranous Nephropathy Correlation with Serum Antibodies to Phospholipase A 2 Receptor (Anti Pla2r)
15. Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets
16. Tiered Pricing in Oncology - Drivers for Improved Patient Access and Commercial Success
17. Improvement in Health-related quality of life for Sickle Cell Disease Patients treated with Chemotherapy-Free Allogeneic Hematopoietic Stem-Cell Transplantation: a Pilot Study
18. Tiered Pricing in Oncology - Drivers for Improved Patient Access and Commercial Success
19. Provincial Hospital Tendering in China: Evaluating The Impact on Price
20. Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets
21. Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets
22. PHP356 - Adoption of Oncology Biosimilars in Europe
23. PSY5 - TREATMENT OUTCOMES IN LUPUS NEPHRITIS CLASS 3 AND 4
24. PUK2 - Clinical Outcomes and Histopathology in Idiopathic Membranous Nephropathy Correlation with Serum Antibodies to Phospholipase A 2 Receptor (Anti Pla2r)
25. PHP43 The High Cost of Treating Cancer: Do Manufacturer Pricing Policies Take Affordability Into Account?
26. PHP78 Similar HTA, Different Access Outcome? Comparison of Orphan Oncology Drug Assessment in South Korea, Australia and the UK
27. PHP66 DEMONSTRATING “DISEASE MODIFYING THERAPIES”? AN HTA PERSPECTIVE
28. PHP60 ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING AND MARKET ACCESS
29. PHP107 BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT
30. PCN30 DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS
31. PHP78 Similar HTA, Different Access Outcome? Comparison of Orphan Oncology Drug Assessment in South Korea, Australia and the UK
32. PCN290 - Tiered Pricing in Oncology - Drivers for Improved Patient Access and Commercial Success
33. PSY60 - Improvement in Health-related quality of life for Sickle Cell Disease Patients treated with Chemotherapy-Free Allogeneic Hematopoietic Stem-Cell Transplantation: a Pilot Study
34. PHP107 BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT
35. PHP17 - Provincial Hospital Tendering in China: Evaluating The Impact on Price
36. PSY9 - Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets
37. PMS28 - Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets
38. PMS28 Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets
39. PCN30 DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS
40. PSY9 Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets
41. PCN290 Tiered Pricing in Oncology - Drivers for Improved Patient Access and Commercial Success
42. PHP43 The High Cost of Treating Cancer: Do Manufacturer Pricing Policies Take Affordability Into Account?
43. PSY60 Improvement in Health-related quality of life for Sickle Cell Disease Patients treated with Chemotherapy-Free Allogeneic Hematopoietic Stem-Cell Transplantation: a Pilot Study
44. PHP66 DEMONSTRATING 'DISEASE MODIFYING THERAPIES'? AN HTA PERSPECTIVE
45. PHP17 Provincial Hospital Tendering in China: Evaluating The Impact on Price
46. PUK6 - Pharmacoeconomic Evaluation of Patients Undergoing Hemodialysis At a Tertiary Care Centre.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.